CoChat

Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Body fat distribution is a heritable risk factor for cardiovascular and metabolic disease. In humans, rare Inhibin beta E ( INHBE , activin E) loss-of-function variants are associated with a lower waist-to-hip ratio and protection from type 2 diabetes. Hepatic fatty acid sensing promotes INHBE expression during fasting and in obese individuals, yet it is unclear how the hepatokine activin E governs body shape and energy metabolism. Here, we uncover activin E as a regulator of adipose energy storage. By suppressing β-agonist-induced lipolysis, activin E promotes fat accumulation and adipocyte hypertrophy and contributes to adipose dysfunction in mice. Mechanistically, we demonstrate that activin E elicits its effect on adipose tissue through ACVR1C, activating SMAD2/3 signaling and suppressing PPARG target genes. Conversely, loss of activin E or ACVR1C in mice increases fat utilization, lowers adiposity, and drives PPARG-regulated gene signatures indicative of healthy adipose function. Our studies identify activin E–ACVR1C as a metabolic rheostat promoting liver–adipose cross talk to restrain excessive fat breakdown and preserve fat mass during prolonged fasting, a mechanism that is maladaptive in obese individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2309967120

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Activin E lowers fat mobilization and increases adiposity in mice. (A) Liver mRNA levels of Inhbe (n = 10). (B) Body weights in 7- to 14-wk-old male Control AAV and Inhbe AAV-treated WT mice (n = 10). (C) Weights of visceral (epididymal) and subcutaneous (inguinal) white adipose tissue (n = 10). (D) Adipocyte morphology and size distribution measured by imaging software in H&E-stained epididymal WAT sections (n = 534,046 cells for Control AAV and 525,314 cells for Inhbe AAV analyzed from 10 mice/group). (E) Ex vivo lipolysis with epididymal WAT explants from WT mice under basal and isoproterenol-stimulated conditions. Fat mobilization is determined enzymatically by glycerol measurements in supernatant (n = 5). (F) Plasma NEFA levels (n = 10). (G) Epididymal WAT mRNA levels of genes involved in adipose lipolysis, relative to Control AAV (n = 10). Mean ± SEM are shown in all graphs besides (D), where mean is shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to Control AAV.
Fig. 1. Activin E lowers fat mobilization and increases adiposity in mice. (A) Liver mRNA levels of Inhbe (n = 10). (B) Body weights in 7- to 14-wk-old male Control AAV and Inhbe AAV-treated WT mice (n = 10). (C) Weights of visceral (epididymal) and subcutaneous (inguinal) white adipose tissue (n = 10). (D) Adipocyte morphology and size distribution measured by imaging software in H&E-stained epididymal WAT sections (n = 534,046 cells for Control AAV and 525,314 cells for Inhbe AAV analyzed from 10 mice/group). (E) Ex vivo lipolysis with epididymal WAT explants from WT mice under basal and isoproterenol-stimulated conditions. Fat mobilization is determined enzymatically by glycerol measurements in supernatant (n = 5). (F) Plasma NEFA levels (n = 10). (G) Epididymal WAT mRNA levels of genes involved in adipose lipolysis, relative to Control AAV (n = 10). Mean ± SEM are shown in all graphs besides (D), where mean is shown. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 relative to Control AAV.CC BY-NC-ND · PubMed Central
Fig. 2. Activin E regulates glycemic control and liver lipid content in mice. (A–D) Liver weights and lipid content. Fasted liver weight (A) and hepatic triglyceride content (B) in Control AAV or Inhbe AAV-treated mice on HFD (n = 9 to 10). Nonfasted liver weight (C) and hepatic triglyceride content (D) in Control AAV or Inhbe AAV-treated mice on HFD (n = 9 to 10). (E) Fasting plasma insulin levels before (baseline) and 3 wk after Inhbe AAV administration on chow (n = 9). (F and G) Glycemic control in Inhbe overexpressing mice. Oral glucose tolerance (F) and insulin tolerance tests (G) in mice administered with Control AAV or Inhbe AAV and fed chow or high-fat diets (n = 10). Mean ± SEM are shown in all graphs. **P < 0.01, ***P < 0.001.
Fig. 2. Activin E regulates glycemic control and liver lipid content in mice. (A–D) Liver weights and lipid content. Fasted liver weight (A) and hepatic triglyceride content (B) in Control AAV or Inhbe AAV-treated mice on HFD (n = 9 to 10). Nonfasted liver weight (C) and hepatic triglyceride content (D) in Control AAV or Inhbe AAV-treated mice on HFD (n = 9 to 10). (E) Fasting plasma insulin levels before (baseline) and 3 wk after Inhbe AAV administration on chow (n = 9). (F and G) Glycemic control in Inhbe overexpressing mice. Oral glucose tolerance (F) and insulin tolerance tests (G) in mice administered with Control AAV or Inhbe AAV and fed chow or high-fat diets (n = 10). Mean ± SEM are shown in all graphs. **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 3. Loss of activin E promotes fat mobilization. (A) Body weights in 7- to 24-wk-old male WT and Inhbe−/− mice on chow and high-fat diet (HFD) (n = 7 to 8). (B and C) Weights of epididymal (B) and subcutaneous (C) white adipose tissue of Inhbe−/− mice following 16 wk of HFD (n = 8). (D) Ex vivo lipolysis with epididymal WAT explants from WT and Inhbe−/− mice under basal and isoproterenol-stimulated conditions (n = 10 to 11). (E and F) Fasted plasma NEFA (E) and beta-hydroxybutyrate (F) levels before (chow) and after 10 or 16 wk of HFD (n = 8). (G) Epididymal WAT mRNA levels of genes involved in adipose lipolysis (n = 6 to 10). (H and I) Fasted liver weight (H) and hepatic triglyceride content (I) in WT and Inhbe−/− mice on HFD (n = 8). (J) Oral glucose tolerance and insulin tolerance tests (K) in WT and Inhbe−/− mice on chow and high-fat diets (n = 7 to 8). (L) Plasma insulin levels before (baseline chow) and 16 wk after HFD (n = 8). (M) Plasma ALT levels in Inhbe−/− mice on chow and HFD for 16 wk. Mean ± SEM are shown in all graphs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 3. Loss of activin E promotes fat mobilization. (A) Body weights in 7- to 24-wk-old male WT and Inhbe−/− mice on chow and high-fat diet (HFD) (n = 7 to 8). (B and C) Weights of epididymal (B) and subcutaneous (C) white adipose tissue of Inhbe−/− mice following 16 wk of HFD (n = 8). (D) Ex vivo lipolysis with epididymal WAT explants from WT and Inhbe−/− mice under basal and isoproterenol-stimulated conditions (n = 10 to 11). (E and F) Fasted plasma NEFA (E) and beta-hydroxybutyrate (F) levels before (chow) and after 10 or 16 wk of HFD (n = 8). (G) Epididymal WAT mRNA levels of genes involved in adipose lipolysis (n = 6 to 10). (H and I) Fasted liver weight (H) and hepatic triglyceride content (I) in WT and Inhbe−/− mice on HFD (n = 8). (J) Oral glucose tolerance and insulin tolerance tests (K) in WT and Inhbe−/− mice on chow and high-fat diets (n = 7 to 8). (L) Plasma insulin levels before (baseline chow) and 16 wk after HFD (n = 8). (M) Plasma ALT levels in Inhbe−/− mice on chow and HFD for 16 wk. Mean ± SEM are shown in all graphs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 4. Activin E signals via ACVR1C to suppress PPARG in adipose tissue. (A) Body weight increase in 7- to 11-wk-old male WT mice treated with control monoclonal antibody (mAb) or neutralizing ACVR1C mAb while on HFD (n = 8 to 9). (B–D) Fasted weights of epididymal (B) and subcutaneous (C) white adipose tissue and liver (D) (n = 8 to 9). (E) Plasma insulin levels before (baseline) and 2 or 4 wk after Control mAb or ACVR1C neutralizing mAb administration to WT mice (n = 8 to 9). (F) Insulin tolerance test in WT and Acvr1c−/− mice on high-fat diet (n = 10). (G to I) Fasted weights of epididymal (G) and subcutaneous (H) white adipose tissue and liver (I) 6 wk following Control AAV or Inhbe AAV administration to WT or Acvr1c−/− mice on chow diet (n = 11). (J and K) Epididymal WAT mRNA levels of activin target genes Pmepa1 and Serpine1 (J), and adipose transcription factor Pparg (K), relative to Control AAV in WT and Acvr1c−/− mice (n = 10 to 11). Mean ± SEM are shown in all graphs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 4. Activin E signals via ACVR1C to suppress PPARG in adipose tissue. (A) Body weight increase in 7- to 11-wk-old male WT mice treated with control monoclonal antibody (mAb) or neutralizing ACVR1C mAb while on HFD (n = 8 to 9). (B–D) Fasted weights of epididymal (B) and subcutaneous (C) white adipose tissue and liver (D) (n = 8 to 9). (E) Plasma insulin levels before (baseline) and 2 or 4 wk after Control mAb or ACVR1C neutralizing mAb administration to WT mice (n = 8 to 9). (F) Insulin tolerance test in WT and Acvr1c−/− mice on high-fat diet (n = 10). (G to I) Fasted weights of epididymal (G) and subcutaneous (H) white adipose tissue and liver (I) 6 wk following Control AAV or Inhbe AAV administration to WT or Acvr1c−/− mice on chow diet (n = 11). (J and K) Epididymal WAT mRNA levels of activin target genes Pmepa1 and Serpine1 (J), and adipose transcription factor Pparg (K), relative to Control AAV in WT and Acvr1c−/− mice (n = 10 to 11). Mean ± SEM are shown in all graphs. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 5. Activin E promotes a gene signature related to adipose dysfunction. (A) Heat map of epididymal adipose transcriptome signatures comparing Inhbe overexpression, Inhbe KO on chow and high-fat diet (HFD) vs. control-treated or WT mice, respectively. (B) Dot plots showing top biological pathways for oppositely regulated genes (Inhbe overexpression vs. KO) in epididymal WAT. (C) Heatmap showing examples of oppositely regulated genes (Inhbe overexpression vs. KO) in epididymal WAT. (D) Relative gene expression levels of PPARG target genes in epididymal WAT, comparing Inhbe KO and WT mice on high-fat diet. (E) Heatmap of epididymal adipose transcriptome signatures comparing WT chow vs. HFD, and Inhbe KO vs. WT on high-fat diet (HFD), demonstrating that Inhbe LOF reverses many of the HFD effects seen in WT mice. (F) Dot plots showing top biological pathways for genes increased in epididymal WAT of Inhbe KO vs. WT on HFD.
Fig. 5. Activin E promotes a gene signature related to adipose dysfunction. (A) Heat map of epididymal adipose transcriptome signatures comparing Inhbe overexpression, Inhbe KO on chow and high-fat diet (HFD) vs. control-treated or WT mice, respectively. (B) Dot plots showing top biological pathways for oppositely regulated genes (Inhbe overexpression vs. KO) in epididymal WAT. (C) Heatmap showing examples of oppositely regulated genes (Inhbe overexpression vs. KO) in epididymal WAT. (D) Relative gene expression levels of PPARG target genes in epididymal WAT, comparing Inhbe KO and WT mice on high-fat diet. (E) Heatmap of epididymal adipose transcriptome signatures comparing WT chow vs. HFD, and Inhbe KO vs. WT on high-fat diet (HFD), demonstrating that Inhbe LOF reverses many of the HFD effects seen in WT mice. (F) Dot plots showing top biological pathways for genes increased in epididymal WAT of Inhbe KO vs. WT on HFD.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. R. C. Adam Transcriptome analysis of adipose tissue of Inhbe knockout and over-expressing mice. NCBI Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231444. Deposited 1 May 2023.

Cited by

See all 44

Metadata

Authors
Adam, R. C., Pryce, D. S., Lee, J. S., Zhao, Y., Mintah, I. J., Min, S., Halasz, G., Mastaitis, J., Atwal, G. S., Aykul, S., Idone, V., Economides, A. N., Lotta, L. A., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V.
Affiliations
  • Regeneron (United States) (US)
  • Regeneron Pharmaceuticals, Tarrytown, NY 10591
Corresponding author
  • Yancopoulos, George D.
  • Gusarova, Viktoria
Venue
Proceedings of the National Academy of Sciences
Published
2023-07-31
Volume
120
Issue
32
Pages
e2309967120-e2309967120
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4385409675
Cited by
44
References
55
Citations by year
2026: 16 · 2025: 13 · 2024: 12 · 2023: 3
FWCI
8.79
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
adipose tissue lipolysis, adipocyte hypertrophy, adipose tissue dysfunction, Smad2/3 signaling, energy metabolism, fasting, obesity, body fat distribution, hepatokines
MeSH terms
Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Humans, Lipolysis, Obesity, Activins, Activin Receptors, Type I, PPAR gamma, Adiposity, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice. https://app.cochat.ai/papers/10.1073/pnas.2309967120
The paper
Adam, R. C., Pryce, D. S., Lee, J. S., Zhao, Y., Mintah, I. J., Min, S., Halasz, G., Mastaitis, J., Atwal, G. S., Aykul, S., Idone, V., Economides, A. N., Lotta, L. A., Murphy, A. J., Yancopoulos, G. D., Sleeman, M. W., & Gusarova, V. (2023). Activin E–ACVR1C cross talk controls energy storage via suppression of adipose lipolysis in mice. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2309967120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.